ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: They are used to manage and treat malignancies like CML and gastrointestinal stromal tumors (GISTs) [2]. They were initially targeted to the platelet-derived growth factor receptor. Subsequently noted to inhibit other protein kinases like c-kit and BCR-ABL fusion protein [3].